Tango Therapeutics, Inc. Logo

Tango Therapeutics, Inc.

Developing precision oncology therapies for genetically-defined patients via synthetic lethality.

TNGX | US

Overview

Corporate Details

ISIN(s):
US87583X1090
LEI:
Country:
United States of America
Address:
201 BROOKLINE AVENUE, 2215 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of a new generation of precision oncology medicines. The company leverages the principle of synthetic lethality to develop therapies that take direct aim at specific tumors within genetically defined patient populations. Utilizing a proprietary drug discovery platform that is based on CRISPR technology, Tango identifies novel drug targets to create transformative treatments for cancers with high unmet medical needs. The company's patient-centric approach aims to expand the reach and effectiveness of genetically targeted therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Tango Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Tango Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Tango Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Solid Biosciences Inc. Logo
Advancing gene therapies and technologies for rare neuromuscular and cardiac diseases.
United States of America
SLDB
SOLIGENIX, INC. Logo
Late-stage biopharma developing treatments for rare diseases and public health threats.
United States of America
SNGX
Sonnet BioTherapeutics Holdings, Inc. Logo
Develops targeted cytokine therapies for cancer using a proprietary albumin-binding platform.
United States of America
SONN
Sonoma Pharmaceuticals, Inc. Logo
Develops and sells stabilized HOCl products for wound, skin, eye, nasal, and animal healthcare.
United States of America
SNOA
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria
SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden
SPAGO
Spero Therapeutics, Inc. Logo
Develops novel treatments for multi-drug resistant bacterial infections and rare diseases.
United States of America
SPRO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland
SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden
SPRINT
SPRUCE BIOSCIENCES, INC. Logo
Developing first-in-class therapies for serious, underserved neurological conditions like MPS IIIB.
United States of America
SPRB

Talk to a Data Expert

Have a question? We'll get back to you promptly.